logo-loader
viewVitality Biopharma, Inc.

Vitality Biopharma CEO says cannabinoids have potential for neurological/inflammatory conditions

Vitality Biopharma (OTCQB:VBIO) CEO Robert Brooke tells Proactive Investors about the company's development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of serious neurological and inflammatory disorders.

Brooke says the cannabinoid prodrugs (known as cannabosides) can, upon ingestion, enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. This could be used by people with conditions such as Crohn's, IBS and colitis.

Brooke says cannabinoids also have the potential to be used as an alternative to opiate abuse.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HANetf's Hector McNeil says price of gold is heading towards $3000 by year end

HANeft co-founder Hector McNeil talks to Proactive London's Katie Pilbeam about how the surge in gold above $2000 an ounce is benefiting his company. The platform's largest fund The Royal Mint Physical Gold ETC, which was launched in February has seen huge safe haven flows amid the...

5 hours, 51 minutes ago

2 min read